Determination of zirconium in steels

The determination of zirconium in the range 0.01-0.20% is required for some special alloy steels. A method has been developed, based on initial removal of iron as its chloro-complex by extraction with methyl isobutyl ketone, followed by further extraction after addition of potassium thiocyanate, and determination of the zirconium left in the aqueous phase, with Arsenazo III. The absorbance is measured at 665 nm.     

Flux synthesis of the noncentrosymmetric cluster compounds Cs2SnAs2Q9 (Q = S,Se) containing two different polychalcoarsenite beta-[AsQ4]3- and [AsQ5]3- ligands

Two noncentrosymmetric quaternary tin chalcoarsenates, Cs(2)SnAs(2)S(9) (1) and Cs(2)SnAs(2)Se(9) (2), were synthesized by the polychalcoarsenate flux method. Compound 1 crystallizes in the orthorhombic space group Pmc2(1) with a = 7.386(3) A, b = 14.614(5) A, c = 14.417(5) A, and Z = 4. Compound 2 crystallizes in the monoclinic space group P2(1) with a = 7.715(5) A, b = 17.56(1) A, c = 7.663(5) A, beta = 115.86(1) degrees, and Z = 2. Both structures contain the same tin-centered molecular cluster anions [Sn[AsQ(2)(Q(2))][AsQ(Q(2))(2)]](2)(-) (Q = S, Se) separated by Cs cations. The Sn(4+) ion is in a distorted octahedral environment coordinated by two different pyramidal-shaped tridentate ligands, [AsQ(2)(Q(2))](3)(-) and [AsQ(Q(2))(2)](3)(-). These compounds absorb visible light at energies above 1.98 and 1.45 eV for 1 and 2, respectively. Differential thermal analysis revealed that 1 melts at 350 degrees C and on cooling gives a glass. The glass recrystallizes at 268 degrees C upon subsequent heating. Compound 2 melts at 258 degrees C.     

1-Chloro-2-deoxy-3,5-di-p-toluoyl-D-erythro-pentosyl Chloride - A Versatile Synthetic Intermediate

Syntheses of 1b-d is described using 1-chloro-2-deoxy-3,5-di-p-toluoyl-D-erythro-pentosyl chloride.     

Oxidative Deoximation with Sodium Perborate1

An efficient and convenient conversion of oximes to corresponding carbonyl compounds with sodium perborate in glacial acetic acid is reported.     

Synthesis of Privileged Scaffolds by Using Diversity‐Oriented Synthesis

An elegant reagent‐controlled strategy has been developed for the generation of a diverse range of biologically active scaffolds from a chiral bicyclic lactam. Reduction of the chiral lactam with LAH or alkylation with LHMDS to trigger different cyclization reactions have been shown to generate privileged scaffolds, such as pyrrolidines, indolines, and cyclotryptamines. Their amenability to substitution allows us to create various compound libraries by using these scaffolds. In silico studies were used to estimate the drug‐like properties of these compounds. Selected compounds were subjected to anticancer screening by using three different cell lines. In addition, all these compounds were subjected to antibacterial screening to gauge the spectrum of biological activity that was conferred by our DOS methodology. Gratifyingly, with no additional iterative cycles, our method directly generated anticancer compounds with potency at low nanomolar concentrations, as represented by spiroindoline 14 .     

Synthesis of 2, 2-Dimethyl-2H-chromenes via a Palladium (II) Catalysed Reaction

The antijuvenile hormones Precocene-I, Precocene-II and other bioactive 2, 2-dimethyl-2H-chromenes have been synthesised by intramolecular oxidative cyclisation of 2-isoprenyl phenols catalysed by a palla-dium(II) salt.     

Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines

A potential new treatment for drug addiction is immunization with vaccines that induce antibodies that can abrogate the addictive effects of the drug of abuse. One of the challenges in the development of a vaccine against drugs of abuse is the availability of an optimum procedure that gives reproducible and high yielding hapten-protein conjugates. In this study, a heroin/morphine surrogate hapten (MorHap) was coupled to bovine serum albumin (BSA) using maleimide-thiol chemistry. MorHap-BSA conjugates with 3, 5, 10, 15, 22, 28, and 34 haptens were obtained using different linker and hapten ratios. Using this optimized procedure, MorHap-BSA conjugates were synthesized with highly reproducible results and in high yields. The number of haptens attached to BSA was compared by 2,4,6-trinitrobenzenesulfonic acid (TNBS) assay, modified Ellman’s test and matrix assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). Among the three methods, MALDI-TOF MS discriminated subtle differences in hapten density. The effect of hapten density on enzyme-linked immunosorbent assay (ELISA) performance was evaluated with seven MorHap-BSA conjugates of varying hapten densities, which were used as coating antigens. The highest antibody binding was obtained with MorHap-BSA conjugates containing 3–5 haptens. This is the first report that rigorously analyzes, optimizes and characterizes the conjugation of haptens to proteins that can be used for vaccines against drugs of abuse. The effect of hapten density on the ELISA detection of antibodies against haptens demonstrates the importance of careful characterization of the hapten density by the analytical techniques described.